Bioventus (NASDAQ:BVS) Stock Rating Cut to Buy at Wall Street Zen

Wall Street Zen downgraded shares of Bioventus (NASDAQ:BVS) from a strong-buy rating to a buy rating in a report published on Saturday morning,Wall Street Zen reports.

A number of other equities research analysts have also recently weighed in on BVS. Canaccord Genuity Group dropped their price objective on Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Barrington Research set a $18.00 target price on Bioventus in a research note on Thursday, August 6th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 target price on shares of Bioventus in a report on Monday, August 17th. Weiss Ratings cut Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Bioventus presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Bioventus Stock Performance

Shares of BVS stock opened at $10.61 on Friday. The firm’s 50 day moving average price is $13.44 and its 200-day moving average price is $10.97. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.17 and a current ratio of 1.68. Bioventus has a one year low of $6.47 and a one year high of $15.89. The firm has a market cap of $892.19 million, a P/E ratio of 13.26, a P/E/G ratio of 1.36 and a beta of 0.66.

Bioventus (NASDAQ:BVS) last posted its earnings results on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. The firm had revenue of $142.44 million during the quarter. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. As a group, equities research analysts predict that Bioventus will post 0.78 EPS for the current year.

Hedge Funds Weigh In On Bioventus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Signaturefd LLC increased its position in shares of Bioventus by 2,809.1% during the third quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock worth $26,000 after acquiring an additional 1,854 shares during the period. USA Financial Formulas purchased a new position in Bioventus in the third quarter valued at $42,000. Covestor Ltd boosted its holdings in Bioventus by 25.6% in the third quarter. Covestor Ltd now owns 5,808 shares of the company’s stock valued at $79,000 after purchasing an additional 1,182 shares during the period. Quantum Financial Partners LLC boosted its holdings in Bioventus by 11.8% in the third quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company’s stock valued at $194,000 after purchasing an additional 1,500 shares during the period. Finally, State of Alaska Department of Revenue grew its stake in Bioventus by 446.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 18,953 shares of the company’s stock worth $258,000 after purchasing an additional 15,484 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.